Lakatos Lehel-Barna, Bolognese Manuel, Österreich Mareike, Weichsel Laura, Müller Martin
Department of Neurology and Neurorehabilitation, Lucerne Kantonsspital, 6000 Lucerne, Switzerland.
Diseases. 2024 Mar 3;12(3):53. doi: 10.3390/diseases12030053.
Whether different antihypertensive drug classes in high blood pressure (HBP) pre-stroke treatment affect dynamic cerebral autoregulation (dCA), stroke severity, and outcome.
Among 337 consecutive ischemic stroke patients (female 102; median age 71 years [interquartile range, [IQR 60; 78]; NIHSS median 3 [IQR 1; 6]) with assessment of dCA, 183 exhibited the diagnosis of HBP. dCA parameters' gain and phase were determined by transfer function analysis of spontaneous oscillations of blood pressure and cerebral blood flow velocity.
Patients used beta-blockers ( = 76), calcium channel blockers (60), diuretics (77), angiotensin-converting enzyme inhibitors (59), or angiotensin-1 receptor blockers (79), mostly in various combinations of two or three drug classes. dCA parameters did not differ between the non-HBP and the different HBP medication groups. Multinomial ordinal logistic regression models revealed that the use of diuretics decreased the likelihood of a less severe stroke (odds ratio 0.691, 95% CI 0.493; 0.972; = 0.01) and that beta-blockers decreased the likelihood of a better modified Rankin score at 3 months (odds ratio 0.981, 95% CI 0.970; 0.992; = 0.009). Other independent factors associated with stroke outcome were penumbra and infarct volume, treatment with mechanical thrombectomy, and the initial National Institute of Health Stroke Scale score.
In this cohort of ischemic minor to moderate stroke patients, pre-stroke antihypertensive treatment with diuretics was associated with a more severe neurological deficit on admission and pre-stroke treatment with beta-blockers with a poorer 3-month outcome. The antihypertensive drug class used pre-stroke did not impact dCA.
高血压(HBP)卒中前治疗中不同类别的降压药物是否会影响动态脑自动调节(dCA)、卒中严重程度及预后。
在337例连续的缺血性卒中患者(女性102例;年龄中位数71岁[四分位间距,IQR 60;78];美国国立卫生研究院卒中量表[NIHSS]中位数3[IQR 1;6])中评估dCA,其中183例诊断为HBP。通过对血压和脑血流速度的自发振荡进行传递函数分析来确定dCA参数的增益和相位。
患者使用β受体阻滞剂(n = 76)、钙通道阻滞剂(60)、利尿剂(77)、血管紧张素转换酶抑制剂(59)或血管紧张素1受体阻滞剂(79),大多为两到三种药物类别的不同组合。非HBP组与不同HBP药物治疗组之间的dCA参数无差异。多项有序逻辑回归模型显示,使用利尿剂可降低卒中不太严重的可能性(比值比0.691,95%置信区间0.493;0.972;P = 0.01),而β受体阻滞剂可降低3个月时改良Rankin评分较好的可能性(比值比0.981,95%置信区间0.970;0.992;P = 0.009)。与卒中预后相关的其他独立因素包括半暗带和梗死体积、机械取栓治疗以及初始美国国立卫生研究院卒中量表评分。
在这组轻度至中度缺血性卒中患者中,卒中前使用利尿剂进行降压治疗与入院时更严重的神经功能缺损相关,而卒中前使用β受体阻滞剂治疗与3个月时较差的预后相关。卒中前使用的降压药物类别不影响dCA。